secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immuneering Corp (IMRX)
CIK:        0001790340
Form:       8-K
Filed at:   2021-09-09T23:59:59+00:00
Accession:  0001558370-21-012334
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immuneering Q2 net loss $7.9M; IPO raised $129.4M; IMM-1-104 IND expected Q1 2022
--------------------------------------------------------------------------------

- Net loss of $7.9M ($1.61/share) vs $3.6M ($0.73/share) in Q2 2020.
- Cash $50.2M at June 30, 2021; excludes $118.3M net IPO proceeds from August 2021.
- R&D expenses $7.0M, up from $3.2M YoY on preclinical costs and personnel.
- Completed upsized IPO of 8.625M shares at $15.00/share for $129.4M gross.
- IND filing for IMM-1-104 (RAF-MEK inhibitor) planned for Q1 2022; Phase 1 start H1 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1790340/000155837021012334/0001558370-21-012334-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1790340/000155837021012334/imrx-20210909x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-012334

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer